ONS President Carl Brown on Key Messages of the Congress

Video

Carlton Brown Describes Key Messages of the ONS Congress

Carlton Brown, RN, PhD, AOCN®, President of the Oncology Nursing Society (ONS) Describes Key Messages of the ONS Congress

Related Videos
Natasha B. Leighl, BSc, MMSc, MD
Ticiana Leal, MD
Marcelo Vailati Negrao, MD
Shirish M. Gadgeel, MD
David Harpole, MD
Pasi A. Jänne, MD, PhD
Guillermo Garcia-Manero, MD
Harry Erba, MD, PhD
Loretta J. Nastoupil, MD
Brad S. Kahl, MD
Related Content

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

September 27th 2023

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26th 2023

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

September 25th 2023

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

September 20th 2023

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

September 20th 2023

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

September 19th 2023

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

September 27th 2023

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26th 2023

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

September 25th 2023

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

September 20th 2023

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

September 20th 2023

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

September 19th 2023

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

September 27th 2023

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26th 2023

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

September 25th 2023

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

September 20th 2023

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

September 20th 2023

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

September 19th 2023